Global Market for Non-Evasive Prenatal Testing to Reach $3.1 Billion by 2023
September 10, 2018
WELLESLEY, Mass., Sep. 10, 2018 – Due to the ability to accurately screen pregnant women for multiple chromosomal conditions without the threat of miscarriage, the global market for non-evasive prenatal testing has reached new heights according to a new report from BCC Research.
In 2018, the global market for non-evasive prenatal testing was worth $1.9 billion. BCC Research estimates that it will reach a value of $3.1 billion by 2023, indicating a compound annual growth rate (CAGR) of 10.2%, according to Next Generation Sequencing for Non-Evasive Prenatal Testing: Global Insights.
Major companies that are influencing the industry include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories and Quest Diagnostics, Inc.
Research Highlights
- The companies/laboratories offering NIPT services include Ariosa (USA): Harmony, BGI Health (China): NIFTY, Illumina (USA): Verifi, Natera (USA): Panorama, Premaitha (UK): IONA, and Sequenom (USA): MATERNIT21 PLUS.
- The implementation of NIPT is facing significant ethical and regulatory hurdles due to the belief that it will increase the number of abortions.
- The Asia-Pacific region is expected to have the fastest growth rate during the forecasted period at 17.3% between 2018 and 2023.
“North America held the largest share of the global NIPT market in terms of revenue,” the report notes. “This can be attributed to the presence of major players in the U.S. and relatively high awareness levels about NIPT in North America. Europe is the second largest market for NIPT. In Europe, market growth largely depends upon increasing penetration of U.S. based tests and their increasing acceptance.”
Editors/reporters requesting analyst interviews should contact Eric Surber at press@bccresearch.com.
Next Generation Sequencing for Non-invasive Prenatal Testing: Global Insights( BIO173A )
Publish Date: Aug 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
- Global Botanical and Plant-Derived Drug Market Projected to Hit $58.1 Billion by 2030
- Global Protein Expression Market Poised for 10.9% CAGR Expansion by 2030
- BCC Research Forecasts 7.5% CAGR for Global Biological Cancer Therapies Market
- Fusion Proteins Market to Hit $64.9 Billion by 2030
Reports from Cell Biology
- Global DNA Read, Write, and Edit Market
- Validation, Calibration, and Standardization in the Life Sciences Market
- Cloud Computing in Cell Biology, Genomics and Drug Development: Global Markets
- Decentralized Clinical Trials: Global Markets
- Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
Recent News
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast